ERYTECH PHARMA (ERYP.PA) Stock Fundamental Analysis

EPA:ERYP • FR0011471135

0.801 EUR
+0 (+0.25%)
Last: Jun 28, 2023, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Taking everything into account, ERYP scores 2 out of 10 in our fundamental rating. ERYP was compared to 77 industry peers in the Biotechnology industry. ERYP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ERYP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ERYP has reported negative net income.
  • In the past year ERYP has reported a negative cash flow from operations.
ERYP.PA Yearly Net Income VS EBIT VS OCF VS FCFERYP.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • ERYP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ERYP.PA Yearly ROA, ROE, ROICERYP.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ERYP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERYP.PA Yearly Profit, Operating, Gross MarginsERYP.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ERYP remains at a similar level compared to 1 year ago.
  • ERYP has a better debt/assets ratio than last year.
ERYP.PA Yearly Shares OutstandingERYP.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
ERYP.PA Yearly Total Debt VS Total AssetsERYP.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.53, we must say that ERYP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ERYP (-2.53) is comparable to the rest of the industry.
  • ERYP has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ERYP (0.44) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -2.53
ROIC/WACCN/A
WACC5.06%
ERYP.PA Yearly LT Debt VS Equity VS FCFERYP.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.
  • ERYP has a Current ratio of 3.65. This is in the better half of the industry: ERYP outperforms 72.84% of its industry peers.
  • A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.
  • ERYP has a better Quick ratio (3.65) than 75.31% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
ERYP.PA Yearly Current Assets VS Current LiabilitesERYP.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.68% over the past year.
  • ERYP shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.04%.
  • ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%

3.2 Future

  • Based on estimates for the next years, ERYP will show a very strong growth in Earnings Per Share. The EPS will grow by 26.28% on average per year.
  • The Revenue is expected to decrease by -44.77% on average over the next years. This is quite bad
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ERYP.PA Yearly Revenue VS EstimatesERYP.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
ERYP.PA Yearly EPS VS EstimatesERYP.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ERYP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ERYP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERYP.PA Price Earnings VS Forward Price EarningsERYP.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERYP.PA Per share dataERYP.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ERYP's earnings are expected to grow with 26.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ERYP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ERYTECH PHARMA

EPA:ERYP (6/28/2023, 7:00:00 PM)

0.801

+0 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.84M
Revenue(TTM)7.66M
Net Income(TTM)-17.28M
Analysts42.22
Price Target3.67 (358.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)307.94%
Min Revenue beat(2)-81.61%
Max Revenue beat(2)697.48%
Revenue beat(4)1
Avg Revenue beat(4)118.61%
Min Revenue beat(4)-81.61%
Max Revenue beat(4)697.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.25
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.25
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -2.53
F-Score4
WACC5.06%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)458.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A

ERYTECH PHARMA / ERYP.PA FAQ

What is the ChartMill fundamental rating of ERYTECH PHARMA (ERYP.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ERYP.PA.


What is the valuation status for ERYP stock?

ChartMill assigns a valuation rating of 2 / 10 to ERYTECH PHARMA (ERYP.PA). This can be considered as Overvalued.


Can you provide the profitability details for ERYTECH PHARMA?

ERYTECH PHARMA (ERYP.PA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ERYP stock?

The Earnings per Share (EPS) of ERYTECH PHARMA (ERYP.PA) is expected to grow by 22.35% in the next year.